Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Nurix Therapeutics, Inc. (NRIX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
19.89-3.35 (-14.41%)
At close: 04:00PM EST
19.89 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23.24
Open22.70
Bid19.85 x 800
Ask19.81 x 800
Day's Range19.77 - 22.70
52 Week Range19.77 - 51.46
Volume459,636
Avg. Volume348,341
Market Cap887.345M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

    Nurix leads protein modulation field with four active clinical stage programs Anticipates data-rich 2022 with clinical-stage programs and a pipeline fueled by proprietary DELigase platform SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today outlined key objectives and anticipated milestones for 2022 and provided an overview of recent progress. “2021 was a significant and highly p

  • GlobeNewswire

    Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix will present an overview of corporate performance in 2021 and major goals for 2022 at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 5:15 pm ET. The presentation will be webcast live and may be accessed v

  • GlobeNewswire

    Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

    U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948 crosses the blood‑brain barrier in preclinical models enabling potential dual development in oncology and autoimmune diseases of the central nervous system NX‑5948 reduces tumor burden and extends survival in a preclinical model of primary central nervous system lymphoma SAN FRANCISCO, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX),

Advertisement
Advertisement